NEUROCRINE BIOSCIENCES INC (NBIX) earnings date, results and what the price requires
Nasdaq · SEC CIK 0000914475 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $959.0M | $144.4M | $1.39 | Filing |
| Mar 31, 2026 | May 5, 2026 | $814.5M | $197.9M | $1.91 | Filing |
| Dec 31, 2025 | Feb 11, 2026 | $805.5M | $153.7M | $1.49 | Filing |
| Sep 30, 2025 | Oct 28, 2025 | $794.9M | $209.5M | $2.04 | Filing |
| Jun 30, 2025 | Jul 30, 2025 | $687.5M | $107.5M | $1.06 | Filing |
| Mar 31, 2025 | May 5, 2025 | $572.6M | $7.9M | $0.08 | Filing |
| Dec 31, 2024 | Feb 6, 2025 | $627.7M | $103.1M | $1.00 | Filing |
| Sep 30, 2024 | Oct 30, 2024 | $622.1M | $129.8M | $1.24 | Filing |
What would NEUROCRINE BIOSCIENCES INC have to report for its valuation to change?
At $136.95, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 11.4% a year, to $11.71. On that path the next quarter needs diluted EPS near $2.27, against $2.04 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 11.4% | 11.4% |
| EPS needed in final year | $11.71 | $11.71 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. NBIX goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.